<DOC>
	<DOCNO>NCT01107886</DOCNO>
	<brief_summary>The purpose study determine whether saxagliptin reduce risk cardiovascular event use alone added diabetes medication</brief_summary>
	<brief_title>Does Saxagliptin Reduce Risk Cardiovascular Events When Used Alone Added Other Diabetes Medications</brief_title>
	<detailed_description>A Multicentre , Randomised , Double-Blind , Placebo-Controlled Phase IV Trial Evaluate Effect Saxagliptin Incidence Cardiovascular Death , Myocardial Infarction Ischaemic Stroke Patients Type 2 Diabetes</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Patients type 2 diabetes mellitus HbA1c â‰¥6.5 % . ( base last measured document laboratory measurement within 6 month ) High risk CV event Established cardiovascular disease and/or multiple risk factor Current previous ( within 6 month ) treatment DPP4 inhibitor and/or GLP1 mimetics Acute vascular event &lt; 2months prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Risk cardiovascular disease death patient type 2 diabetes mellitus</keyword>
</DOC>